📊 PHAT Key Takeaways
Is Phathom Pharmaceuticals, Inc. (PHAT) a Good Investment?
Phathom demonstrates exceptional 217% revenue growth with strong 87% gross margins, indicating product viability; however, the company faces critical financial distress with negative stockholders' equity of -$438M, operating losses of -$160M, and cash burn of -$167M annually against only $130M in cash reserves, creating acute solvency and liquidity risk.
Why Buy Phathom Pharmaceuticals, Inc. Stock? PHAT Key Strengths
- Exceptional revenue growth of 216.9% YoY demonstrates strong market demand
- High gross margin of 87.1% indicates viable product economics and pricing power
- Current ratio of 1.73x provides near-term liquidity for operational obligations
PHAT Stock Risks: Phathom Pharmaceuticals, Inc. Investment Risks
- Negative stockholders' equity of -$438.2M indicates technical insolvency and potential bankruptcy
- Operating cash burn of -$166.8M annually against $130M cash creates ~9-month runway
- Operating margin of -91.4% and net margin of -126.3% show unsustainable cost structure with no clear profitability path
- Negative interest coverage of -4.6x indicates inability to service debt from operations
- Long-term debt of $209.1M with negative equity creates refinancing risk
Key Metrics to Watch
- Monthly operating cash flow trend and cash balance depletion rate
- Operating expense reduction initiatives and path to operating breakeven
- Revenue growth sustainability and gross margin maintenance
- Debt refinancing activity and capital raise announcements
Phathom Pharmaceuticals, Inc. (PHAT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Phathom Pharmaceuticals, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
PHAT Profit Margin, ROE & Profitability Analysis
PHAT vs Healthcare Sector: How Phathom Pharmaceuticals, Inc. Compares
How Phathom Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Phathom Pharmaceuticals, Inc. Stock Overvalued? PHAT Valuation Analysis 2026
Based on fundamental analysis, Phathom Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Phathom Pharmaceuticals, Inc. Balance Sheet: PHAT Debt, Cash & Liquidity
PHAT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Phathom Pharmaceuticals, Inc.'s revenue has grown significantly by 25,576% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.29 indicates the company is currently unprofitable.
PHAT Revenue Growth, EPS Growth & YoY Performance
PHAT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $16.4M | -$30.0M | $-0.41 |
| Q2 2025 | $7.3M | -$75.8M | $-1.05 |
| Q1 2025 | $1.9M | -$82.9M | $-1.31 |
| Q3 2024 | N/A | -$37.8M | $-0.76 |
| Q2 2024 | N/A | -$37.8M | $-0.84 |
| Q1 2024 | N/A | -$37.8M | $-0.89 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Phathom Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
PHAT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Phathom Pharmaceuticals, Inc. (CIK: 0001783183)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PHAT
What is the AI rating for PHAT?
Phathom Pharmaceuticals, Inc. (PHAT) has an AI rating of STRONG SELL with 90% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PHAT's key strengths?
Claude: Exceptional revenue growth of 216.9% YoY demonstrates strong market demand. High gross margin of 87.1% indicates viable product economics and pricing power.
What are the risks of investing in PHAT?
Claude: Negative stockholders' equity of -$438.2M indicates technical insolvency and potential bankruptcy. Operating cash burn of -$166.8M annually against $130M cash creates ~9-month runway.
What is PHAT's revenue and growth?
Phathom Pharmaceuticals, Inc. reported revenue of $175.1M.
Does PHAT pay dividends?
Phathom Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find PHAT SEC filings?
Official SEC filings for Phathom Pharmaceuticals, Inc. (CIK: 0001783183) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PHAT's EPS?
Phathom Pharmaceuticals, Inc. has a diluted EPS of $-3.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PHAT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Phathom Pharmaceuticals, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PHAT stock overvalued or undervalued?
Valuation metrics for PHAT: ROE of N/A (sector avg: 15%), net margin of -126.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PHAT stock in 2026?
Our dual AI analysis gives Phathom Pharmaceuticals, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PHAT's free cash flow?
Phathom Pharmaceuticals, Inc.'s operating cash flow is $-166.8M, with capital expenditures of $229.0K. FCF margin is -95.4%.
How does PHAT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -126.3% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.73 (avg: 2).